ClinicalTrials.gg

Program

tavapadon

Also written as “Tavapadon”, “PF-06649751” and “0.5 mg PF-06649751”.

Its studies are mostly in Parkinson Disease · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Dec 13, 201920 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie110 open or runningphase 3since Dec 13, 2019Dec 13, 2019none ahead
Pfizer90 open or runningphase 2since Jan 29, 2016Nov 5, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 5, 2013.

  1. Feb 20, 2015Phase 1 study in Parkinson DiseasePfizer · NCT02373072 · 18 enrolled · United States, Belgium
  2. Jan 29, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02687542 · 108 enrolled · United States, Canada, France and more
  3. Jul 25, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02847650 · 57 enrolled · United States, France, Germany and more
  4. Apr 7, 2017Phase 1 study in HealthyPfizer · NCT03121664 · 11 enrolled · Belgium
  5. Jun 9, 2017Phase 2 study in Parkinson DiseasePfizer · NCT03185481 · 5 enrolled · United States
  6. Dec 13, 2019AbbVie's first study: phase 3 study in Parkinson DiseaseNew to AbbVieAbbVie · NCT04201093 · 529 enrolled · United States, Australia, Bulgaria and more
  7. Jan 7, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04223193 · 304 enrolled · United States, Australia, France and more
  8. Jan 22, 20202 phase 1 studiesAbbVie · NCT04241393, NCT04295642
  9. Sep 2, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04542499 · 507 enrolled · United States, Australia, Bulgaria and more
  10. Feb 12, 2021Phase 3 study in Parkinson DiseaseAbbVie · NCT04760769 · 992 enrolled · United States, Australia, Bulgaria and more
  11. May 30, 20222 phase 1 studiesAbbVie · NCT05404542, NCT05404529
  12. Oct 12, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05581823 · 16 enrolled · United States
  13. Nov 2, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05610189 · 25 enrolled · United States
  14. Mar 20, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT06895356 · 83 enrolled · United States

TargetBeta

DRD1 →DRD5 →read by rule
“Dopamine D1 receptor partial agonist; Dopamine D5 receptor partial agonist”ChEMBL 37, by rule

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06895356Healthy Volunteer · United States1CompletedAbbVieJun 16, 202583
NCT05610189Parkinson Disease · United States1CompletedAbbVieDec 12, 202325
NCT05581823Parkinson Disease · United States1CompletedAbbVieJan 27, 202316
NCT05404542Renal Insufficiency · United States1CompletedAbbVieAug 14, 202314
NCT05404529Hepatic Impairment · United States1CompletedAbbVieJan 24, 202332
NCT04760769Parkinson Disease · United States, Australia, Bulgaria and more3CompletedAbbVieDec 1, 2025992
NCT04542499Parkinson Disease · United States, Australia, Bulgaria and more3CompletedAbbVieJan 29, 2024507
NCT04295642Parkinson Disease · United States1CompletedAbbVieJul 23, 202124
NCT04241393Healthy Subjects · United States1CompletedAbbVieNov 8, 202012
NCT04223193Parkinson Disease · United States, Australia, France and more3CompletedAbbVieOct 1, 2024304
NCT04201093Parkinson Disease · United States, Australia, Bulgaria and more3CompletedAbbVieJun 28, 2024529
NCT03185481Parkinson Disease · United States2TerminatedPfizerOct 24, 20175
NCT03121664Healthy · Belgium1CompletedPfizerSep 14, 201711
NCT02847650Parkinson Disease · United States, France, Germany and more2TerminatedPfizerJan 29, 201857
NCT02687542Parkinson Disease · United States, Canada, France and more2TerminatedPfizerNov 10, 2017108
NCT02373072Parkinson Disease · United States, Belgium1CompletedPfizerFeb 201618
NCT02262767Healthy · Belgium1CompletedPfizerDec 20149
NCT02224664Parkinson Disease · United States, Belgium1CompletedPfizerMar 201650
NCT02066909Healthy · United States1CompletedPfizerApr 201577
NCT01981694Healthy · United States1CompletedPfizerFeb 201418

How it is read

Names in the registry

  • “Tavapadon”, 10 entries
  • “PF-06649751”, 9 entries
  • “0.5 mg PF-06649751”, 2 entries
  • “CVL-751”, 1 entry
  • “PF-06649751 low dose (1 mg QD)”, 1 entry

Codes read as this program: PF06649751.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.